Medical News

RSS

Short courses of antibiotics have long-term impact on microbial flora of human gut

Short courses of antibiotics can leave normal gut bacteria harbouring antibiotic resistance genes for up to two years after treatment, say scientists writing in the latest issue of Microbiology, published on 3 November.

1 Nov 2010

GlycosBio, Malaysian Bio-XCell enter agreement to build biochemical plant and biotechnology R&D facility

Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today exchanged definitive agreements with Malaysian Bio-XCell for the establishment of the Company's industrial biochemical plant and biotechnology R&D facility in Malaysia

1 Nov 2010

Kaplan EduNeering opens new office in Hong Kong

Kaplan EduNeering, a leading provider of compliance and knowledge management solutions, announces today the opening of a Hong Kong office to serve clients based in Asia. The new location, which will house sales and support staff, is based in the Hong Kong offices of its parent company, Kaplan, Inc. In 2008, Kaplan EduNeering opened a European-based location in Reading, England.

1 Nov 2010

Gore announces new Early TIPS for Ascites Study

W.L. Gore & Associates (Gore) today announced a new prospective, randomized, multi-center study at the Annual Meeting of the American Association for the Study of Liver Diseases. The hypothesis of the study is that early intervention with the GORE® VIATORR® TIPS Endoprosthesis improves transplant-free survival when compared to large volume paracentesis in patients with cirrhosis and difficult to treat ascites.

1 Nov 2010

Momenta reports $32.1M net income for third quarter 2010 vs. $14.6M net loss for third quarter 2009

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced its financial results for the quarter ended September 30, 2010.

1 Nov 2010

HealthAlliance of the Hudson Valley to implement REACH3's CRM solution

REACH3 - healthcare CRM's market leader, enabling robust provider and payer marketing initiatives through secure, cloud-based technology - announced today that HealthAlliance of the Hudson Valley has chosen to implement its CRM Custom solution to strengthen its consumer and patient marketing campaigns, as well as enhance the unified brand identity of its newly formed health system.

1 Nov 2010

Porex sells surgical division to Stryker

Porex Corporation, a portfolio company of Los Angeles-based investment firm Aurora Capital Group, today announced that it has sold its Porex Surgical division to Stryker Corporation.

From Stryker 1 Nov 2010

XOMA receives final $2.0 million from Kaketsuken under antibody technology collaboration

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced receipt of the final $2.0 million payment from Kaketsuken under the $8.0 million collaboration announced in November 2009. The agreement involves multiple proprietary XOMA antibody research and development technologies, including a new XOMA phage display library, and a suite of integrated information and data management systems.

1 Nov 2010

Varian's Acuros XB dose calculation algorithm for radiotherapy receives FDA 510(k) clearance

Varian Medical Systems has received FDA 510(k) clearance for the Acuros® XB advanced dose calculation algorithm which can complete a RapidArc® treatment plan two to three times faster than conventional planning algorithms. Varian has incorporated the Acuros algorithm for external beam radiotherapy treatment planning into its market-leading Eclipse™ treatment planning system on exhibit at the 52nd annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego October 31 - November 4.

1 Nov 2010

Aegerion underwriters exercise over-allotment option

Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.

1 Nov 2010

Pasteurized human breast milk recommended alternative for hospitalized sick newborns

Pasteurized human milk is a recommended alternative for hospitalized sick newborns when their own mother's milk is not available, according to a new statement by the Canadian Paediatric Society. The statement, published today in Paediatrics & Child Health, says that human milk banking in Canada should be encouraged and promoted.

1 Nov 2010

Cato Research selects BioClinica's clinical trial management system

BioClinica®, Inc.,, a global provider of clinical trial management solutions, today announced a new agreement with Cato Research Ltd., a full-service contract research organization. Cato Research selected BioClinica's clinical trial management system (CTMS) platform in its search for a best-in-class solution to better serve its growing worldwide client base.

From Clario 1 Nov 2010

LHC Group enters joint venture with Rockcastle Regional Hospital and Respiratory Care Center

LHC Group, Inc., a national provider of home health and hospice, announced today that it has entered into a home health joint venture with Rockcastle Regional Hospital and Respiratory Care Center, located in Mount Vernon, Kentucky to provide home health services in Rockcastle County in the Certificate of Need (CON) state of Kentucky.

1 Nov 2010

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

NanoViricides, Inc. reported today that its FluCide drug candidates demonstrated dramatically improved survival in animals administered a lethal dose of influenza virus. Animals treated with all of the different influenza nanoviricide drug candidates survived for dramatically longer periods as compared to Tamiflu treated animals.

1 Nov 2010

Edleun acquires three child care centres in Alberta

Edleun Group, Inc., a leading consolidator, operator and developer of child care facilities in Canada, announced today that it has completed its acquisition of the previously announced three child care centres located in Calgary, Alberta. The acquisition of these three centres adds 283 licensed childcare spaces to the Company's portfolio and increases the total number of spaces to 1,851. Including the transaction just completed, Edleun currently owns 20 centres in Canada.

1 Nov 2010

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Nycomed today announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources.

1 Nov 2010

PreViser releases new web-based tool for oral health

PreViser Corporation announced today the release of a Web based tool, myDentalScore, that allows individuals to calculate objective numeric scores for oral disease risk and severity.

1 Nov 2010

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has received clearance from Health Canada to commence a Phase II human clinical trial with its H5N1 Avian Influenza vaccine ("H5N1 vaccine"). Enrolment of volunteers is now underway.

1 Nov 2010

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

Oncolytics Biotech Inc. today announced that an abstract covering preclinical research with reovirus (REOLYSIN) is available on the European CanCer Organisation (ECCO). The research is scheduled to be presented at the 22nd EORTC-NCI-AACR symposium on Molecular Targets and Cancer Therapeutics being held in Berlin, Germany from November 16th - 19th 2010.

1 Nov 2010

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Discovery Laboratories, Inc. today announced that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis (CF).

1 Nov 2010

Medical News

Short courses of antibiotics have long-term impact on microbial flora of human gut

GlycosBio, Malaysian Bio-XCell enter agreement to build biochemical plant and biotechnology R&D facility

Kaplan EduNeering opens new office in Hong Kong

Gore announces new Early TIPS for Ascites Study

Momenta reports $32.1M net income for third quarter 2010 vs. $14.6M net loss for third quarter 2009

HealthAlliance of the Hudson Valley to implement REACH3's CRM solution

Porex sells surgical division to Stryker

XOMA receives final $2.0 million from Kaketsuken under antibody technology collaboration

Varian's Acuros XB dose calculation algorithm for radiotherapy receives FDA 510(k) clearance

Aegerion underwriters exercise over-allotment option

Pasteurized human breast milk recommended alternative for hospitalized sick newborns

Cato Research selects BioClinica's clinical trial management system

LHC Group enters joint venture with Rockcastle Regional Hospital and Respiratory Care Center

Lab study shows nanoviricide drug candidate improves survival rate in influenza viral infection

Edleun acquires three child care centres in Alberta

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

PreViser releases new web-based tool for oral health

Medicago receives Health Canada clearance for Phase II clinical trial of H5N1 Avian Influenza vaccine

Oncolytics to present REOLYSIN data for multiple myeloma at EORTC-NCI-AACR symposium

FDA grants orphan drug designation to Discovery's KL4 surfactant for CF treatment

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News